Lisa Taft
Emory University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Lisa Taft.
American Journal of Medical Genetics | 1998
Sallie B. Freeman; Lisa Taft; Kenneth J. Dooley; Katherine Allran; Stephanie L. Sherman; Terry Hassold; Muin J. Khoury; Denise Saker
Mental retardation and hypotonia are found in virtually all Down syndrome (DS) individuals, whereas congenital heart defects (CHDs) are only present in a subset of cases. Although there have been numerous reports of the frequency of CHDs in DS, few of the studies have had complete ascertainment of DS in a defined geographic area. The Atlanta Down Syndrome Project, a population-based study of infants born with trisomy 21, provides such a resource. In the first 6.5 years of the study, 243 trisomy 21 livebirths were identified in the five-county Atlanta area (birth prevalence: 9.6/10,000). Cardiac diagnoses were available on 227 (93%) of the cases and 89% of these evaluations were made by echocardiography, cardiac catheterization, surgery, or autopsy. Of the 227 DS infants, 44% had CHDs including 45% atrioventricular septal defect (with or without other CHDs), 35% ventricular septal defect (with or without other CHDs), 8% isolated secundum atrial septal defect, 7%, isolated persistent patent ductus arteriosus, 4% isolated tetralogy of Fallot, and 1% other. This report is unique in that it contains the largest number of trisomy 21 infants ascertained in a population-based study where modern techniques for diagnosing cardiac abnormalities predominate.
American Journal of Human Genetics | 2000
Sallie B. Freeman; Quanhe Yang; Katherine Allran; Lisa Taft; Stephanie L. Sherman
Advanced maternal age is the only well-established risk factor for trisomy 21 Down syndrome (DS), but the basis of the maternal-age effect is not known. In a population-based, case-control study of DS, women who reported surgical removal of all or part of an ovary or congenital absence of one ovary were significantly more likely to have delivered a child with DS than were women who did not report a reduced ovarian complement (odds ratio 9.61; 95% confidence interval 1.18-446.3). Because others have observed that women who have had an ovary removed exhibit elevated levels of FSH and similar hallmarks of advanced maternal age, our finding suggests that the physiological status of the ovary is key to the maternal-age effect. In addition, it suggests that women with a reduced ovarian complement should be offered prenatal diagnosis.
American Journal of Human Genetics | 1999
Dana C. Crawford; Kellen L. Meadows; James L. Newman; Lisa Taft; Dorothy Pettay; Laura B. Gold; S. Jane Hersey; Elizabeth F. Hinkle; Mary L. Stanfield; Patricia Holmgreen; Marshalyn Yeargin-Allsopp; Coleen A. Boyle; Stephanie L. Sherman
We conducted a large population-based survey of fragile X (FRAXA) syndrome in ethnically diverse metropolitan Atlanta. The eligible study population consisted of public school children, aged 7-10 years, in special education-needs (SEN) classes. The purpose of the study was to estimate the prevalence among whites and, for the first time, African Americans, among a non-clinically referred population. At present, 5 males with FRAXA syndrome (4 whites and 1 African American), among 1,979 tested males, and no females, among 872 tested females, were identified. All males with FRAXA syndrome were mentally retarded and had been diagnosed previously. The prevalence for FRAXA syndrome was estimated to be 1/3,460 (confidence interval [CI] 1/7,143-1/1,742) for the general white male population and 1/4, 048 (CI 1/16,260-1/1,244) for the general African American male population. We also compared the frequency of intermediate and premutation FRAXA alleles (41-199 repeats) and fragile XE syndrome alleles (31-199 repeats) in the SEN population with that in a control population, to determine if there was a possible phenotype consequence of such high-repeat alleles, as has been reported previously. No difference was observed between our case and control populations, and no difference was observed between populations when the probands were grouped by a rough estimate of IQ based on class placement. These results suggest that there is no phenotype consequence of larger alleles that would cause carriers to be placed in an SEN class.
Genetics in Medicine | 1999
Quanhe Yang; Stephanie L. Sherman; Terry Hassold; Katherine Allran; Lisa Taft; Dorothy Pettay; Muin J. Khoury; J. David Erickson; Sallie B. Freeman
Purpose: We examined maternal smoking and oral contraceptive use as possible risk factors in the genesis of cases of trisomy 21 of maternal origin. This is the first epidemiological study to categorize cases of trisomy 21 by parent of origin and timing of the meiotic error before assessing possible risk factors.Methods: We used chromosome 21-specific DNA markers to assign origin to each case. Structured interviews were employed to deter-mine maternal smoking and oral contraceptive use around conception.Results: The odds ratio (OR) for maternal smoking was significantly increased among younger mothers (OR = 2.98; 95% CI = 1.01–8.87), but only in a particular subset of meiotically-derived cases. The combined use of cigarettes and oral contraceptives increased the risk further (OR = 7.62; 95% CI = 1.63–35.6); however, oral contraceptive use alone was not a significant risk factor.Conclusion: Our results indicate that categorizing cases of trisomy 21 by parent and timing of the meiotic error allows more precision in identifying risk factors and may shed light on mechanisms of meiotic nondisjunction.
Journal of Genetic Counseling | 2005
Aimee Anido; Lisa M. Carlson; Lisa Taft; Stephanie L. Sherman
Fragile X syndrome (FXS) is primarily due to a repeat expansion mutation found in the FMR1 X-linked gene. We have conducted a qualitative analysis of responses from women concerning their attitudes toward testing for carrier status of the fragile X mutation among reproductive-age women. We obtained responses from focus groups including women with and without FXS in their families. We found the following themes: (1) mothers of children with FXS have difficulty formulating their opinions on population screening because of their unique experiences surrounding their own carrier diagnosis and their relationship with their children with FXS, (2) the motivation for carrier testing and need for information differ by family history of FXS and parental status, and (3) the timing of carrier testing with respect to a woman’s life stage dictates whether carrier information will be viewed as beneficial or detrimental. There was evidence that non-carrier women from the general population would be wholly unprepared for positive carrier results. These findings have significant implications for genetic counseling as well as for population screening.
Human Genetics | 1998
M. Hixon; Elise Millie; Lu Ann Judis; Stephanie L. Sherman; Katherine Allran; Lisa Taft; Terry Hassold
Abstract Paternal nondisjunction accounts for approximately 5% of cases of trisomy 21. To test the hypothesis that, in some such cases, the fathers might be predisposed to meiotic nondisjunction, we utilized fluorescence in situ hybridization (FISH) to screen for aneuploidy in sperm. We analyzed sperm samples from ten males with a trisomy 21 offspring of paternal origin. Among these individuals, the overall frequency of disomy 21 was 0.15%, comparable to estimates of disomy 21 in the general male population. Furthermore, none of the ten fathers of trisomy 21 individuals had significantly elevated levels of disomic sperm. Thus, our results provide no evidence that the occurrence of a trisomy 21 conceptus of paternal origin imparts an increased risk of trisomy in subsequent pregnancies.
Nature Genetics | 1996
Neil E. Lamb; Sallie B. Freeman; Amanda Savage-Austin; Dorothy Pettay; Lisa Taft; Jane Hersey; Yuanchao Gu; Joe Shen; Denise Saker; Kristen M. May; Dimitris Avramopoulos; Michael B. Petersen; Anni Hallberg; Margareta Mikkelsen; Terry Hassold; Stephanie L. Sherman
Human Molecular Genetics | 1997
Neil E. Lamb; Eleanor Feingold; Amanda Savage; Dimitris Avramopoulos; Sallie B. Freeman; Yuanchao Gu; Anni Hallberg; Jane Hersey; Georgia Karadima; Dorothy Pettay; Denise Saker; Joe Shen; Lisa Taft; Margareta Mikkelsen; Michael B. Petersen; Terry Hassold; Stephanie L. Sherman
Human Molecular Genetics | 1994
Stephanie L. Sherman; Michael B. Petersen; Sallie B. Freeman; Jane Hersey; Dorothy Pettay; Lisa Taft; Merete Frantzen; Margareta Mikkelsen; Terry Hassold
American Journal of Medical Genetics | 2002
Dana C. Crawford; Kellen L. Meadows; James L. Newman; Lisa Taft; Elizabeth Scott; Mary Leslie; Lisa Shubek; Patricia Holmgreen; Marshalyn Yeargin-Allsopp; Coleen A. Boyle; Stephanie L. Sherman